Fundraising FoxMithril Capital Management — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)in
Board seatAjay Royan· per SEC Form D
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more
Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.
BiotechDeep TechHealthtechMedical DevicesAustin, US
Tillman Gerngross(Executive Officer, Director)
BoardTerrance McGuire(Director)
Board seatAjay Royan· per SEC Form D
Co-investorsGV (Google Ventures)Fidelity InvestmentsPolaris PartnersSands Capital VenturesSpring Mountain Capital
ForSight Robotics develops the JASPER robotic surgery platform, combining robotics, advanced visualization, and AI-driven data analytics to assist ophthalmic surgeons in performing eye surgery.
AI & Machine LearningMedical DevicesRobotics
Daniel Glozman(Founder)Joseph Nathan(Founder)Moshe Shoham(Founder)
Co-investorsEclipse VenturesSonder Capital
Gen H (Generation Home) is a UK mortgage lender offering products such as an "Income Booster" that increases borrowing capacity using support from family and friends, and "New Build Boost," a scheme pairing a mortgage with a 15% interest-free equity loan.
FintechPropTech
Co-investorsEntrée CapitalExpansion CapitalLa FamigliaMS&AD VenturesAtomicoLegal & General+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.